Article PDF first page preview

First page of Dominant dystrophic epidermolysis bullosa with COL7A1 variant confirmed by whole-exome sequencing in a Chinese family and genotype-phenotype correlation analysis

Introduction: Epidermolysis Bullosa (EB) comprises a diverse group of rare, incurable genetic disorders characterized by blistering of the skin. These conditions have variable clinical presentations and poorly understood genotypes and phenotypes. This study aims to confirm the diagnosis of dystrophic epidermolysis bullosa (DEB) in a family and analyze gene-phenotype correlations. Methods: The study involved three patients, two controls, and one member with unknown phenotype. We performed whole exome sequencing (WES) on two family members to identify EB-associated genes, with Sanger sequencing for validation. Results: 1) WES revealed missense variants in the COL7A1 ([c.4274T>C.L1425P] and [c.3602G>A.R1201H]) genes in the family, although recorded in the dbSNP database, they have not been reported in previous articles, and classified as of uncertain significance by InterVar. These findings were confirmed by Sanger sequencing. 2) Statistical analysis indicated a significant association between dystrophic epidermolysis bullosa and epidermolysis bullosa simplex (EBS) with junctional epidermolysis bullosa (JEB) (P=0.031) in dominant and recessive inheritance patterns, respectively. However, no significant correlation was found between the clinical phenotype of DEB and variant types (nonsense and missense), inheritance patterns (dominant and recessive), or between familial and sporadic cases. Conclusion: This study identified variants in the COL7A1 gene within Chinese families, expanding the variant spectrum of DEB. These findings lay the groundwork for improved genetic diagnosis and counseling.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.